Leuprolide acetate

Leuprolide acetate is a synthetic analogue of gonadotropin-releasing hormone (GnRH), a hormone that regulates the release of reproductive hormones from the pituitary gland. It belongs to the GnRH agonist class and is used to manage several hormone-dependent conditions. Initially, leuprolide stimulates the release of luteinising hormone and follicle-stimulating hormone, which can temporarily increase testosterone or oestrogen levels. With continuous administration, it suppresses pituitary hormone signalling, leading to reduced production of these sex hormones. This effect makes leuprolide clinically useful in advanced prostate cancer and selected gynaecological conditions, including endometriosis and uterine fibroids. Certain formulations are also used to treat central precocious puberty in children and in specific assisted reproductive technology protocols. Leuprolide acetate is available in different formulations, including daily subcutaneous injections and long-acting intramuscular or subcutaneous depot injections. The formulation, dose, and administration interval depend on the condition being treated and the patient's clinical needs. Because initial hormone stimulation may temporarily worsen symptoms before suppression occurs, treatment requires appropriate medical supervision. Monitoring helps assess treatment response, adverse effects, hormone suppression, and condition-specific risks. Leuprolide is a prescription medicine and should be used according to the approved indication and product-specific prescribing information.

Leuprolide acetate was developed as a synthetic analogue of naturally occurring GnRH, with greater potency and prolonged biological activity. Its therapeutic effect results from sustained stimulation followed by desensitisation and downregulation of pituitary GnRH receptors, reducing the release of gonadotropins and subsequent sex hormone production. The US Food and Drug Administration (FDA) approved leuprolide products for advanced prostate cancer in the 1980s, with the long-acting Lupron Depot formulation initially approved in 1989. Subsequent approvals expanded its use to selected gynaecological conditions, central precocious puberty, and assisted reproductive treatment protocols, depending on the formulation. The European Medicines Agency (EMA) and national regulatory authorities have authorised various leuprorelin or leuprolide products for specific indications. Approval dates, formulations, and indications differ by country and product. Clinical evidence supporting its use includes studies evaluating testosterone suppression in prostate cancer, symptom control in endometriosis and uterine fibroids, and suppression of premature pubertal hormone activity in children. Prescribers should consult the relevant local product information to confirm the currently approved indications and dosing recommendations.

Leuprolide acetate is used for several hormone-dependent conditions, with approved indications varying according to the formulation and country. In advanced prostate cancer, it suppresses testosterone production and helps control tumour growth. In women, selected formulations are used to manage endometriosis by reducing ovarian hormone production and may be prescribed for the preoperative management of uterine fibroids, including reducing fibroid-related bleeding and improving certain symptoms. Specific formulations are also approved for central precocious puberty, a condition in which puberty begins unusually early in children. Leuprolide may be used in assisted reproductive technology protocols to control pituitary hormone activity and coordinate ovarian stimulation. Depending on the indication, it may be used alone for hormonal suppression or alongside other treatments, such as iron therapy before surgery for fibroids or other prescribed cancer therapies. It is not interchangeable across all indications, and the exact product, formulation, and treatment schedule must be selected according to the patient's diagnosis and applicable prescribing guidance.

Leuprolide acetate is administered by subcutaneous injection, intramuscular injection, or a long-acting depot formulation, depending on the product and indication. In advanced prostate cancer, approved depot schedules include monthly, three-monthly, four-monthly, and six-monthly formulations, with the selected strength determined by the required dosing interval. For endometriosis, monthly or three-monthly formulations may be prescribed for a limited treatment period. Treatment for uterine fibroids is generally time-limited and may be combined with iron supplementation when indicated. In children with central precocious puberty, the dose and interval depend on the specific formulation, body weight, and treatment response. Assisted reproductive protocols follow specialist-directed schedules. These regimens are not interchangeable, and depot products must be administered according to their specific preparation and injection instructions. Treatment duration depends on the indication, response, adverse effects, and approved product information. Clinicians should monitor relevant hormone levels and clinical outcomes, with additional assessments based on the condition being treated.

Common side effects of leuprolide acetate include hot flashes, sweating, headache, fatigue, injection-site pain or irritation, mood changes, reduced sexual desire, and changes in libido. Because the medicine lowers sex hormone levels during continued treatment, some patients may experience vaginal dryness, reduced sexual function, or menstrual changes. In men, breast tenderness and testicular shrinkage may occur. Long-term treatment can reduce bone mineral density, while temporary worsening of symptoms may occur when treatment begins. The type and severity of side effects depend on the indication, dose, formulation, duration, and individual response. Many effects can be managed with appropriate clinical support, but persistent or troublesome symptoms should be discussed with the treating healthcare professional. Patients should not alter the injection schedule or discontinue treatment without medical advice.

Leuprolide acetate can initially increase sex hormone levels before suppressing them. In patients with advanced prostate cancer, this initial hormonal surge may temporarily worsen bone pain, urinary obstruction, or other cancer-related symptoms. In susceptible patients, worsening urinary obstruction or spinal cord compression can cause serious complications and requires urgent assessment. Other important risks include reduced bone density, metabolic changes such as increased blood glucose, cardiovascular events, and prolongation of the QT interval. Seizures and severe allergic reactions have also been reported. Rarely, pituitary apoplexy has occurred, particularly in susceptible patients. Leuprolide may cause fetal harm and should not be used during pregnancy for indications in which it is contraindicated. Treatment should be reassessed if serious adverse reactions occur, hormone suppression is inadequate, or complications develop. Sudden weakness, new severe back pain, loss of bladder or bowel control, chest pain, or a severe allergic reaction requires urgent medical attention.

Before initiating leuprolide acetate, clinicians should review the patient's diagnosis, medical history, pregnancy status where relevant, cardiovascular risk, bone health, and current medicines. Baseline and follow-up assessments may include hormone levels, prostate-specific antigen (PSA), testosterone, blood glucose, lipid profile, bone mineral density, and electrocardiography when clinically indicated. Particular caution is required in patients with osteoporosis, diabetes, cardiovascular disease, a history of seizures, or risk factors for QT prolongation. Medicines that prolong the QT interval may increase the risk of cardiac rhythm disturbances when used with leuprolide. Patients taking medicines that affect glucose control may require closer monitoring. Leuprolide can impair fertility during treatment, and pregnancy prevention should be discussed when appropriate. It is not a vaccine or an immunosuppressive biologic, so vaccine decisions should follow routine clinical guidance and the patient's underlying condition. In children treated for central precocious puberty, growth, pubertal development, and treatment response require specialist monitoring. The formulation-specific prescribing information should be reviewed for contraindications and additional precautions.

Prescribers should confirm the intended indication and select the exact leuprolide formulation before prescribing, as dosing schedules and release characteristics differ among products. Document baseline clinical findings and relevant laboratory measurements, then establish a monitoring plan tailored to the condition. In prostate cancer, monitor testosterone suppression, PSA where appropriate, and symptoms that could indicate an initial tumour flare. For endometriosis and fibroids, assess symptom improvement, treatment duration, and bone health when indicated. For paediatric use, track growth, pubertal signs, and biochemical response. Pharmacists should verify the injection route, reconstitution requirements, storage conditions, administration interval, and product-specific instructions. Counsel patients that symptoms may temporarily worsen at the beginning of treatment and explain which warning signs require urgent assessment. Review concomitant medicines for potential QT-related risks and metabolic concerns. Coordination between oncology, gynaecology, paediatric endocrinology, reproductive medicine, and pharmacy teams helps ensure appropriate treatment selection, safe administration, and timely management of adverse effects.